iTeos Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
iTeos Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
  • iTeos Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $2.26M, a 83.5% increase year-over-year.
  • iTeos Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $5.66M, a 224% increase year-over-year.
  • iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $3.61M, a 93.1% decline from 2022.
  • iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $52.1M, a 24.2% increase from 2021.
  • iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $41.9M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $3.61M -$48.5M -93.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 $52.1M +$10.1M +24.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 $41.9M +$42M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 -$57K +$62K +52.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-23
2019 -$119K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.